Multi-omics analyses across complementary in vitro and in vivo models suggest that MaaT013 modulates biological processes involved in aGvHD pathogenesis, providing exploratory, multi-model evidence of MaaT013's potential to mitigate aGvHD by restoring microbial diversity, gut integrity, and immune homeostasis.
Abstract
Background Acute graft-vs.-host disease (aGvHD) is a life-threatening complication of allogeneic hematopoietic cell transplantation (allo-HCT), where allogeneic donor T cells recognize recipient tissues as foreign and damage them. Gut microbiota disruption following allo-HCT has been associated with increased aGvHD incidence, severity, and mortality. Growing clinical evidence suggests the efficacy of fecal microbiotherapy to restore a healthy and diverse gut microbiota and to treat aGvHD. MaaT013 (Xervyteg®), a standardized allogeneic fecal microbiotherapy derived from pooled healthy human fecal microbiota, has demonstrated efficacy in mitigating steroid-refractory aGvHD in the Phase 2 HERACLES trial, and is currently being evaluated in the pivotal ARES trial in ruxolitinib-resistant aGvHD with gastrointestinal involvement. Methods Here, multi-omics analyses across complementary in vitro and in vivo models suggest that MaaT013 modulates biological processes involved in aGvHD pathogenesis. Results First, MaaT013-derived metabolites prevented inflammation-induced gut barrier alteration in an in vitro leaky gut model. Second, MaaT013 stimulated dendritic cell-mediated Tregs amplification and subsequent release of IL-10 and TGF-b in vitro. Third, beneficial bacteria from MaaT013 engrafted in the gut of germ-free mice, producing anti-inflammatory metabolites and restoring healthy gut physiology through immune rebalancing. Finally, MaaT013 delayed the appearance of aGvHD symptoms in a specific-pathogen free xenogeneic mouse model of aGvHD. Discussion Together, these results provide exploratory, multi-model evidence of MaaT013's potential to mitigate aGvHD by restoring microbial diversity, gut integrity, and immune homeostasis.
Findings support PF as a potential prophylactic candidate for allo-HSCT through coordinated regulation of donor T cell responses, inflammatory mediators, hematopoietic reconstitution, intestinal barrier injury, apoptosis, and gut microbiota, while preserving GVT activity.
Xing-Yu Wan, Nan Li, Yang Gou et al.· Frontiers in Immunology· 0 citations
The intestinal microbiome has emerged as a clinically significant modulator of outcomes across multiple domains of cancer care. In hematopoietic stem cell transplantation (HSCT), loss of microbial diversity and depletion of short-chain fatty acid-producing commensals are independently associated with graft-versus-host...
Ayham Alomari, Abdallah Kheshman, Peter Morkos et al.· Onco· 0 citations
It is found that THL significantly improved survival in aGVHD recipients, reduced weight loss and clinical scores, and attenuated pathological changes in aGVHD target organs, including the liver, small intestine, and colon.
Xin Li, Ke Zhao, Rui Gao et al.· Blood Science· 0 citations
Kidney transplantation represents the optimal treatment for eligible patients with end-stage renal disease (ESRD), yet long-term graft survival remains threatened by rejection, infection, and immunosuppressant-related toxicity. Increasing evidence identifies the gut microbiome as an important modulator of these outcome...
Ya-Long Zhang, Rui Yan, Kang-Yu Wang et al.· European Journal of Pharmaco...· 0 citations
Collectively, microbiome-based approaches may contribute to the development of personalized immunotherapeutic strategies in HCC, although larger standardized prospective studies are required before microbiome-derived biomarkers can be implemented in routine clinical practice.
Mădălina-Raluca Ostafe, S. Volovat, Ana Clement et al.· International Journal of Mol...· 0 citations
The gut microbiota and broader gut microenvironment, comprising microbiota-derived metabolites and host–microbial interactions, have emerged as potentially modifiable factors associated with host immune regulation and have been implicated in altered drug responsiveness, immune-mediated diseases, and metabolic disorders...
Yoshiko Matsuda· Frontiers in Immunology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.